Save time and get answers to complex questions with AI chat
Somatuline generic name?Can i take anti histamine with statin?How to apply for vascepa's patient assistance?Guselkumab patent expiration?Alogliptin benz cost?
See the DrugPatentWatch profile for Dulaglutide
When does the main Trulicity patent expire? The primary U.S. patent covering dulaglutide (Trulicity) – U.S. Pat. 8,719,596 – expires on September 6 2025. This patent protects the molecule and its formulation. What happens after the patent expires? Once the patent lapses, other companies can file for biosimilar approval. The FDA will review these applications to ensure the biosimilar matches the reference product in safety, purity, and potency. Approval could bring lower‑price options to patients and insurers. Are there any other patents that still protect dulaglutide? Yes. Eli Lilly holds additional patents covering manufacturing processes, formulation enhancements, and specific delivery systems. Some of these expire between 2026 and 2029, extending market protection beyond the primary patent. Can biosimilars enter the market now? Biosimilar developers must wait until all relevant patents expire. If they file after 2025, they must demonstrate no infringement on the remaining process or formulation patents that still exist. They can submit an Abbreviated BLA after the final patent lapses. How long is the overall exclusivity period for Trulicity? Trulicity entered the U.S. market in 2014. With the main patent expiring in 2025 and secondary patents extending into the late 2020s, Eli Lilly enjoys roughly 12–15 years of effective exclusivity, depending on the specific claims granted. What about international patent status? In the European Union, the main patent (EP 3 269 000) expires in 2027. In Canada, the relevant patent expires in 2026. Outside the U.S. and EU, patent life varies by country, but many follow the 20‑year rule from filing. Who else is making similar GLP‑1 drugs? Other GLP‑1 receptor agonists—such as semaglutide (Wegovy, Rybelsus) and liraglutide (Victoza, Saxenda)—remain in competition. Their patents expire at different dates: semaglutide’s primary patent in 2024, liraglutide’s in 2028. What should patients and providers expect after 2025? - Potentially lower costs as biosimilars enter. - Continued access to Trulicity until the last relevant patent expires. - Possible changes in insurance coverage or formulary status if cheaper alternatives appear. Source DrugPatentWatch – Dulaglutide patents.
Other Questions About Dulaglutide :